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Abstract
Background: It is commonly agreed that people with a high blood LDL-cholesterol will have a higher risk of
coronary artery disease (CAD) than people with low blood LDL-cholesterol. Due to the increasingly high costs
of medication in Thailand, the government has set up several measures to combat the problem. One of such
strategies is to promote the utilization of locally manufactured drug products, especially those contained in the
National Drug List. Simvastatin, an HMG-CoA reductase inhibitor, is listed as an essential drug for the treatment
of hypercholesterolemia. Here, we reported the study on the LDL-cholesterol-lowering effect of a generic
simvastatin product in comparison with the Zocor©, in 43 healthy thai  volunteers.
Method: The generic product tested  was Eucor©, locally manufactured by Greater Pharma Ltd., Part, Thailand,
and the reference product was Zocor© (Merck Sharp & Dohme, USA). The two products were administered as
10-mg single oral doses in a two-period crossover design. After drug administration, serial blood samples were
collected every 4 weeks for 16 weeks. The major parameter monitored in this study was blood LDL-cholesterol.
Result: After taking the drugs for the first 8 weeks, no statistically significant difference was dedected in blood
LDL-cholesterol between the first (Zocor©-treated) and the second (Eucor©-treated) groups. After crossover
and taking drugs for further 8 weeks, a similar result was obtained, i.e., no significant difference in blood LDL-
cholesterol between the first (Eucor©-treated) and the second (Zocor©-treated) groups was observed. Upon
completion of the 16-week study, there was also no statisticaly significant difference in the changes of all tested
blood parameters between the two products (randomized block ANOVA, N = 37). Only minor side effects,
mainly dizziness and nausea, were observed in both products.
Conclusion: Our study demonstrated no significant differences in the therapeutic effect and safety between the
generic and original simvastatin products.
Introduction
It is commonly agreed that one with high blood LDL-cho-
lesterol level will have higher risk of coronary artery dis-
ease (CAD) than one with low blood LDL-cholesterol
level [1]. Decrease in the blood LDL-cholesterol can slow
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down and reduce the incidence of CAD, and thus the mor-
tality rate associated with the disease [2].
HMG-CoA reductase inhibitors are widely used in the
treatment of hypercholesterolemia due to its high efficacy
in reducing blood LDL-cholesterol [3,4]. One of them,
simvastatin, has been included in Thailand's National
Drug List since 1999. Presently, the majority of simvasta-
tin products available in Thailand are imported from
abroad either as the original product or imported gener-
ics. Only a few are locally manufactured in the country.
To help alleviate the rising cost of imported drugs, one
strategy of the National Drug Policy is to promote the us-
age of locally made generic products [5]. Simvastatin is an
essential drug of which the local production and utiliza-
tion are strongly encouraged, provided that it can give
equivalent safety and efficacy to the original product.
Here, we report the outcome of the first randomized cross-
over study to be conducted in Thailand on the LDL-cho-
lesterol lowering effect of a locally manufactured generic
simvastatin product in comparison with the innovator's
product Zocor©.
Materials and methods
Protocol approval and setting of the study
The study protocol was first sent to the Ethical Committee
of the Faculty of Medicine, Chulalongkorn University, as
well as to the Food and Drug Administration of Thailand
for review. After protocol approval, the study was per-
formed at King Chulalongkorn Memorial Hospital in
Bangkok, which is the largest Thai Red Cross Society Hos-
pital. All laboratory analyses were performed using auto-
mated clinical analyzers at the Department of Laboratory
Medicine, Faculty of Medicine, Chulalongkorn University.
This laboratory is the first Thai laboratory accredited by
ISO 9002: 1994 for the whole process [6].
Preparation of simvastatin
Simvastatin tablets used in this study were from two
sources. The first group was original product (Zocor©), 10
mg per tablet (lot no. W4010, Merck Sharp & Dohme,
USA) whereas the second group was a locally manufac-
tured generic product (Eucor©), 10 mg per tablet (lot no.
RS 10202, Greater Pharma Ltd., Part, Thailand). Zocor©
was directly purchased by the authors from the distribu-
tor. Eucor© was supplied by the local manufacturer.
All the simvastatin tablets from the original and locally-
made sources were individually inserted by the third per-
son into the similarly shaped capsules. The two products
were respectively called drug A and drug B. Study design
was double-blinded such that both the physicians in
charge and the subjects did not know the true identity of
the content inside the capsules.
Thirty capsules were put into a sachet and distributed to
the individual subjects at each visit. They were instructed
to take one capsule daily after an evening meal. The inter-
val between each visit was 4 weeks. All subjects received
physical examination and blood tests at each visit. They
were also advised to practice diet control and regular exer-
cise during the entire period of study.
Study design and protocol
Primary assumptions
1. The population under study is representative of Thai
population with hypercholesterolemia (blood LDL-cho-
lesterol ≥  160 mg/dL)
2. All drug capsules in this study had the same pharma-
ceutical properties, i.e., equal amount of active ingredient,
similar in vitro release and dissolution profiles
Screening visit
After giving a written informed consent, each volunteer re-
ceived physical examination and laboratory screening test
(complete blood count, fasting blood sugar, glucose,
BUN, creatinine, electrolyte, liver function test, CPK, total
cholesterol, HDL-cholesterol, LDL-cholesterol and triglyc-
eride).
The initial inclusion criteria of the subjects were 1) age be-
tween 30 and 70 years old, 2) fasting plasma LDL-choles-
terol ≥  160 mg/dL, 3) no previous history of using any
antilipemic drugs, 4) no pregnancy (urine pregnancy test
must be negative) and 5) voluntary participation by sign-
ing a consent form. The initial exclusion criteria were 1)
history of allergy to HMG-CoA reductase inhibitors, 2)
pregnancy or lactation, 3) perimenopause or menopause,
4) having personal illnesses such as diabetes mellitus, liv-
er diseases, renal diseases, thyroid diseases, ischemic heart
disease or epilepsy, 5) past and present use of cyclosporin,
digoxin, erythromycin, gemfibrozil, niacin, vitamin B3,
warfarin, immunosuppressive agents or any other drugs
with reported interaction with simvastatin, 6) heavy
drinking habit of tea or coffee (≥  1,000 ml/day), 7) heavy
smoking (≥  20 cigarettes/day), 8) serum aminotransferase
more than three times normal, and 9) serum CPK more
than three times normal.
During the first 4 weeks before taking the drugs (run-in
period), all subjects were advised to practice diet control
and regular exercise according to the Guideline for the
Clinical Evaluation of Lipid Altering Agents in Adult and
Children, September 1990 (USFDA), under the supervi-
sion of the Division of Nutrition and Endocrinology, King
Chulalongkorn Memorial Hospital. They were also cau-
tioned against any practice that may lead to the conditions
of exclusion criteria.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/1
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Study visit
After a 4-week run-in period, 43 subjects who had passed
the screening laboratory tests and met all other inclusion
criteria were included in the study. They were randomly
allocated into 2 groups for participation in a randomized
crossover study without washout period [7,8]. The first
group received drug A for 8 weeks, then switched to drug
B for another 8 weeks. Vice versa, the second group took
drug B for the first 8 weeks followed by drug A for another
8 weeks.
During the 16 weeks of drug intake, the individual sub-
jects were followed up at a 4-week interval, thereby mak-
ing a total of 4 study visits. At each visit, they were
interviewed and physically examined for any possible side
effects. They were also tested for plasma lipid profiles
(triglyceride, total cholesterol, HDL- and LDL-cholesterol)
and other blood chemistry parameters such as serum ami-
notransferase and CPK. They were dropped out from the
study if the latter two parameters exceeded three times the
normal values. Additional exclusion of subjects was set in
cases of 1) development of serious side effects, and 2)
poor subject compliance (taking 20% less capsules than
normal or refusal to continue drug intake). The primary
outcome to be focused in this study was blood LDL-cho-
lesterol.
Statistical analysis
The study was designed with the sufficient number of sub-
jects to ensure that it had the power to detect 10% differ-
ence in the effect, if such difference existed. Appropriate
statistical analyses were employed in this study [7–9]. In
brief, we selected ANCOVA analysis, using the initial
measure of LDL-cholesterol and other biochemical pa-
rameters previously mentioned as covariates, and after-
wards, testing the period, sequence, treatment and subject
effects as in the classical model of MANOVA crossover de-
sign. Unpaired t-test comparisons were also done in the
middle of the study. All statistical analyses were per-
formed at 5% significance level.
Results
After run-in period, 43 subjects passed the inclusion crite-
ria to participate in the core study. 22 subjects were ran-
domly allocated into the first group and 21 in the second
group. There were no significant differences in the age and
all the blood chemistry parameters between the two
groups in this pre-medication period (Unpaired t-test, P >
0.05) (Table 1). ANCOVA also revealed that there was no
significant effect of other covariates on LDL-cholesterol.
After taking drugs for the first 8-week period, 2 subjects in
the second group were excluded from the study due to mi-
nor drug side effect (dizziness and nausea). Data in Table
2 show that all the blood chemistry parameters, including
Table 1: Characteristics of the subjects in both groups at initial visit (before taking drugs)
Parameters mean ± standard deviation (90 % confidence interval) P-value
1st group (N = 22) 2nd group (N = 21)
Age (years) 48.90 ± 10.83 48.45 ± 9.36 NS
(45.01–52.79) (45.17–51.73)
Total cholesterol (mg/dL) 259.30 ± 31.83 254.40 ± 33.47 NS
(247.87–270.73) (242.66–266.14)
HDL (mg/dL) 45.50 ± 12.27 44.80 ± 10.04 NS
(41.10–49.90) (41.28–43.32)
Triglyceride (mg/dL) 160.00 ± 90.71 168.40 ± 89.23 NS
(127.44–192.56) (137.11–199.69)
LDL (mg/dL) 181.90 ± 25.33 175.90 ± 30.71 NS
(172.81–190.99) (165.13–186.67)
Sgot (U/L) 26.40 ± 10.33 24.50 ± 8.38 NS
(22.69–30.11) (21.56–27.44)
Sgpt (U/L) 30.00 ± 15.26 31.30 ± 20.95 NS
(24.52–35.48) (23.95–38.65)
CPK (U/L) 123.80 ± 68.94 125.70 ± 73.54 NS
(99.05–148.55) (99.91–151.49)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/1
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the LDL-cholesterol, were similar between the two groups
at the end of the first 8 weeks (Unpaired t-test, P > 0.05).
At the end of the first period, all the subjects in the first
group switched brands from A to B and the second group
from B to A. The medication was then continued for fur-
ther 8 weeks. At the end of this period (16th week), one
subject in the first group and 3 subjects in the second
group dropped out due to failure to comply with the ad-
ministration protocol (not due to drug-related side ef-
fects), thus leaving a total of 37 subjects to complete the
study. All subjects were found to have good drug tolerance
regardless of the brand taken. Similarly, data in Table 3
also reveal that there were no significant differences in the
lipid and other blood chemistry parameters between the
two groups (Unpaired t-test, P > 0.05).
Randomized block ANOVA also showed no significant
differences in the LDL-cholesterol level and other blood
chemistry parameters between product A and product B
over the entire 16 weeks (N = 37, P > 0.05). The 90% con-
fidence interval for the difference in the LDL-cholesterol
between A and B was 0–12.96 mg/dL.
Discussion
To cope with the problems of increasing demand for med-
icines and to help reduce the costs of imported finished
pharmaceutical products, a number of developing coun-
tries including Thailand have set up several strategies, one
of which is to promote the local manufacture and usage of
quality generic drugs. For any generic products to be ap-
proved by the regulatory authority, scientific evidence
about the product safety and efficacy must be demonstrat-
ed [10]. In this article, we reported the outcome of the first
randomized crossover study in Thailand, which compared
the clinical efficacy of a locally manufactured generic 10
mg simvastatin tablets with that of original, imported
product (10 mg Zocor© tablets) in 43 healthy Thai volun-
teers with hypercholesterolemia.
In general, study to establish bioequivalence between the
original and the generic products involves measurements
of the drug level or active metabolite(s) in the blood,
which is based on a pharmacokinetic approach. However,
measurements of plasma simvastatin concentration
proved to be more difficult because the drug is in an inac-
tive lactone form which is preferentially taken up by the
liver, the target site of action. Simvastatin has a high liver
uptake after gastrointestinal absorption, with hepatic ex-
traction ratio greater than 90%. Less than 5% of the simv-
astatin dose was reported to reach the systemic circulation
in healthy human volunteers [11]. Thus, most of the drug
will accumulate in the liver, where it is metabolized to sev-
eral active compounds, the major one of which is simvas-
tatin acid. The active metabolites will act by inhibiting
hepatic enzyme HMG-CoA reductase, thereby interfering
with the synthesis of endogenous cholesterol in the liver.
Apparently, accurate determination of extremely low con-
centrations of simvastatin metabolite(s) in the blood
could be very difficult to achieve. And even if it is possible,
it may not represent the actual amount of drug accumulat-
ing in the target organ and thus, it may not provide good
correlation to the drug therapeutic result.
Table 2: Characteristics of the subjects in both groups after taking drugs for 8 weeks
Parameters mean ± standard deviation (90 % confidence interval) P-value
1st group (N = 22) 2nd group (N = 19)
Total cholesterol (mg/dL) 191.80 ± 37.41 198.90 ± 31.48 NS
(178.37–205.23) (187.02–210.78)
HDL (mg/dL) 45.50 ± 8.38 50.80 ± 10.49 NS
(42.49–48.51) (46.84–54.76)
Triglyceride (mg/dL) 140.90 ± 69.49 129.20 ± 78.59 NS
(115.96–165.84) (99.54–158.86)
LDL (mg/dL) 118.20 ± 30.92 122.30 ± 22.43 NS
(107.10–129.30) (113.84–130.76)
SGOT (U/L) 28.60 ± 12.71 28.50 ± 15.35 NS
(24.04–33.16) (22.71–34.29)
SGPT (U/L) 35.80 ± 27.02 34.80 ± 26.71 NS
(26.10–45.50) (24.72–44.88)
CPK (U/L) 125.80 ± 55.61 119.60 ± 57.17 NS
(105.84–145.76) (98.02–141.76)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/1
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In this case, indirect study by measurements of its phar-
macodynamic or therapeutic effect can provide a good
resolution [12]. A study design based on a clinical ap-
proach was utilized here to compare the safety and effica-
cy of a generic simvastatin with that of the original
product. Similar to the general bioequivalence study
based on plasma drug concentration measurements, stud-
ies employing a clinical/pharmacodynamic approach can
provide useful information on the quality of the locally
made products so as to assure both the physicians and the
patients that the products can produce equivalent thera-
peutic outcome.
However, there are a number of variables to be concerned
in this type of study. Differences in the individual subjects'
physiology, age, sex, lifestyle, diet and exercise control, as
well as compliance, can lead to great variation in the ther-
apeutic response. Control of these factors is very impor-
tant. Thus, strict inclusion and exclusion criteria have
been observed throughout this study. Closed monitoring
of the patient compliance was also carried out by direct in-
terview of the individual subjects as well as by checking
the amount of the capsules remaining after each visit. To
further control the variation, the number of subjects was
carefully calculated to account for the increased variability
associated with the dynamic nature of the study [13–15].
A conventional bioequivalence study using a crossover de-
sign with plasma drug concentration measurement will
usually requires 12–24 subjects. In our study, however,
the number of subjects was calculated to have sufficient
power to detect at least 10% difference in the primary out-
come (blood LDL-cholesterol level). By using the above
condition and the standard deviation from the previous
clinical trial [16], the value of 17 subjects was obtained.
The total number of subjects in this study was 43, which
was acceptable for statistical analysis (even in the case of
several dropouts) based on the hypothesis that both drugs
provided no difference in the primary therapeutic out-
come [16,17].
According to the result of this study conducted in Thai hy-
percholesterolemic subjects without other related diseases
(DM, CAD, etc.), there was no statistical significant differ-
ence between the two products with regards to changes in
blood LDL-cholesterol either at 8 weeks or 16 weeks (P >
0.05). The result indicated that the two products were
equivalent in terms of efficacy. Also, other blood chemis-
try parameters were found to be similar such as the triglyc-
eride level and hepatic enzyme activities.
Apart from direct evaluation of the therapeutic result, an-
other advantage of the clinical study over the convention-
al bioequivalence test is the ability to compare the drug
unwanted side effects. The side effects reported here (diz-
ziness and nausea) may or may not relate to the drug.
Some reported drug side effects in clinical trials may also
originate from the placebo known as the placebo effects.
However, it is also possible that the side effects may be
due to the presence of impurities or the inclusion of inap-
propriate " inert" excipients in the drug formula. In this
study, the incidence of the side effect was mild. Only two
subjects in the second group reported symptoms of dizzi-
ness and/or nausea and voluntarily withdrew from the
study. A few other subjects in both groups reported the
Table 3: Characteristics of the subjects in both groups after crossover and continuation of drug for further 8 weeks
Parameters mean ± standard deviation (90 % confidence interval) P-value
1st group (N = 21) 2nd group (N = 16)
Total cholesterol (mg/dL) 200.30 ± 36.86 182.40 ± 17.24 NS
(187.07–213.53) (175.31–189.49)
HDL (mg/dL) 47.40 ± 9.64 49.40 ± 10.38 NS
(43.94–50.86) (45.13–53.67)
Triglyceride (mg/dL) 142.40 ± 62.54 127.40 ± 58.40 NS
(119.95–164.85) (103.38–151.42)
LDL (mg/dL) 124.40 ± 31.70 107.50 ± 14.65 NS
(113.02–135.78) (101.48–113.52)
SGOT (U/L) 25.10 ± 7.96 23.90 ± 9.50 NS
(22.24–27.96) (19.99–27.81)
SGPT (U/L) 37.60 ± 22.32 30.60 ± 21.79 NS
(29.59–45.61) (21.64–39.56)
CPK (U/L) 106.20 ± 42.49 118.40 ± 42.35 NS
(90.95–121.45) (100.98–135.82)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/1
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same symptoms but remained in the study until comple-
tion. In general, the subjects appeared to have good toler-
ance for both products and the frequency of side effect
was similar. The rest of the dropouts were due to non-
compliance (failure to adhere to the administration rou-
tine).
Conclusion
The result from this comparative study showed that the
10-mg generic simvastatin tablet produced in Thailand
(Lot no. RS 10202, Greater Pharma) showed no statistical
significant difference in the change in blood LDL-choles-
terol, either at 8 weeks or 16 weeks (after crossover), from
the original 10-mg Zocor© tablet (Lot no. W4010; Merck,
Sharp and Dohme). No difference in the side effects was
also detected between the two products based on symp-
tom observation and hepatic enzyme activity measure-
ments. Both products were well tolerated by the subjects
without any serious side effects.
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